Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Recruiting 4Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 13Gastrointestinal 11Thoracic 7Other solid neoplasm 6Genitourinary 6Breast 4Sarcoma 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Advanced Solid Tumor 3Solid Tumor 1Advanced Solid Tumors 1Advanced Malignant Solid Tumors 1

Interventions

pembrolizumab 30Injections 26Pemetrexed 15Interviews as Topic 15tislelizumab 13Specimen Handling 13Carboplatin 13Cisplatin 12Nivolumab 11atezolizumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Bevacizumab 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Platinum 6Paclitaxel 6Leucovorin 6Ipilimumab 6Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
toripalimab × Other solid neoplasm × 90 days × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

NCT04322006 2026-05-13

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

TJ Biopharma Co., Ltd.

Phase 1/2 Completed
225 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03810339 2026-04-23

Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Sun Yat-sen University

Phase 2 Recruiting
35 enrolled
Other solid neoplasm

Solid Tumor

NCT06832982 2026-04-09

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Shanghai Pushi Medical Science Co. Ltd

Phase 1 Recruiting
66 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT07508761 2026-04-02

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Nanjing Immunophage Biotech Co., Ltd

Phase 1/2 Not yet recruiting
52 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
86 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡